PL3337506T3 - Kombinacje i ich zastosowania - Google Patents

Kombinacje i ich zastosowania

Info

Publication number
PL3337506T3
PL3337506T3 PL16756997T PL16756997T PL3337506T3 PL 3337506 T3 PL3337506 T3 PL 3337506T3 PL 16756997 T PL16756997 T PL 16756997T PL 16756997 T PL16756997 T PL 16756997T PL 3337506 T3 PL3337506 T3 PL 3337506T3
Authority
PL
Poland
Prior art keywords
combinations
applications
Prior art date
Application number
PL16756997T
Other languages
English (en)
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PL3337506T3 publication Critical patent/PL3337506T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
PL16756997T 2015-08-21 2016-08-18 Kombinacje i ich zastosowania PL3337506T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15181925 2015-08-21
PCT/EP2016/069571 WO2017032679A1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof
EP16756997.9A EP3337506B1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof

Publications (1)

Publication Number Publication Date
PL3337506T3 true PL3337506T3 (pl) 2022-01-03

Family

ID=54010888

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16756997T PL3337506T3 (pl) 2015-08-21 2016-08-18 Kombinacje i ich zastosowania

Country Status (23)

Country Link
US (3) US11224654B2 (pl)
EP (2) EP3337506B1 (pl)
JP (4) JP6862422B2 (pl)
KR (2) KR20180042335A (pl)
CN (2) CN115054697B (pl)
AU (3) AU2016311136B2 (pl)
CA (1) CA2995738A1 (pl)
CY (1) CY1124706T1 (pl)
DK (1) DK3337506T3 (pl)
ES (1) ES2891336T3 (pl)
HR (1) HRP20211291T1 (pl)
HU (1) HUE056408T2 (pl)
IL (2) IL257345B2 (pl)
LT (1) LT3337506T (pl)
MX (2) MX392561B (pl)
PL (1) PL3337506T3 (pl)
PT (1) PT3337506T (pl)
RS (1) RS62260B1 (pl)
RU (1) RU2767063C2 (pl)
SI (1) SI3337506T1 (pl)
SM (1) SMT202100541T1 (pl)
WO (1) WO2017032679A1 (pl)
ZA (1) ZA201801052B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3337506T1 (sl) 2015-08-21 2021-12-31 Morphosys Ag Kombinacije in njihove uporabe
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
IL270855B2 (en) 2017-05-31 2023-03-01 Morphosys Ag A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
AU2020375149A1 (en) * 2019-10-31 2022-05-12 Incyte Corporation Sequential anti-CD19 therapy
JP2023551519A (ja) * 2020-11-30 2023-12-08 インサイト・コーポレイション 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法
IL313736A (en) * 2021-12-22 2024-08-01 Incyte Corp Treatment paradigm for CD19 antibody therapy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
MXPA02010618A (es) 2000-04-25 2004-05-05 Icos Corp Inhibidores de fosfatidilinositol 3-quinasa delta.
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
JP5825756B2 (ja) * 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
AU2007294575B2 (en) 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
SG173654A1 (en) 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
NZ598732A (en) * 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
CA2815363C (en) * 2010-10-22 2020-07-14 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
HRP20220224T1 (hr) * 2011-08-16 2022-04-29 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
EP2744515B1 (en) * 2011-08-16 2022-02-09 MorphoSys AG Combination therapy with an anti-cd19 antibody and a nitrogen mustard
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9808753B2 (en) 2013-02-15 2017-11-07 3M Innovative Properties Company System and method for making pleated filter media
AU2015277516A1 (en) 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
PL3302550T3 (pl) 2015-05-26 2020-02-28 Morphosys Ag Kombinacja przeciwciała anty-cd19 i inhibitora kinazy tyrozynowej brutona i jej zastosowania
SI3337506T1 (sl) 2015-08-21 2021-12-31 Morphosys Ag Kombinacije in njihove uporabe
SG11201810159TA (en) 2016-05-30 2018-12-28 Morphosys Ag Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
CN109415440B (zh) 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
IL270855B2 (en) 2017-05-31 2023-03-01 Morphosys Ag A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2022532519A (ja) 2019-05-03 2022-07-15 モルフォシス・アーゲー 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
TWI883067B (zh) 2019-10-31 2025-05-11 美商英塞特公司 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
AU2020375149A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Sequential anti-CD19 therapy
JP7813225B2 (ja) 2019-10-31 2026-02-12 インサイト・コーポレイション 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法
CA3181827A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
JP2023551519A (ja) 2020-11-30 2023-12-08 インサイト・コーポレイション 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法
CA3204063A1 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
IL313736A (en) 2021-12-22 2024-08-01 Incyte Corp Treatment paradigm for CD19 antibody therapy

Also Published As

Publication number Publication date
LT3337506T (lt) 2021-10-11
AU2022202800B2 (en) 2024-01-04
US20250195646A1 (en) 2025-06-19
AU2016311136B2 (en) 2022-02-17
CN107921129B (zh) 2022-05-27
EP3337506B1 (en) 2021-07-21
EP3954388A1 (en) 2022-02-16
CN107921129A (zh) 2018-04-17
HK1247122A1 (zh) 2018-09-21
CN115054697B (zh) 2024-06-11
AU2024202109A1 (en) 2024-05-02
KR20180042335A (ko) 2018-04-25
IL257345B (en) 2022-11-01
ES2891336T3 (es) 2022-01-27
EP3337506A1 (en) 2018-06-27
ZA201801052B (en) 2021-05-26
MX2018002241A (es) 2018-03-23
KR102786010B1 (ko) 2025-03-26
HUE056408T2 (hu) 2022-02-28
BR112018003263A2 (pt) 2018-09-25
IL257345B2 (en) 2023-03-01
CY1124706T1 (el) 2022-07-22
AU2016311136A1 (en) 2018-03-01
MX392561B (es) 2025-03-24
IL257345A (en) 2018-03-29
HRP20211291T1 (hr) 2021-12-10
US11224654B2 (en) 2022-01-18
SI3337506T1 (sl) 2021-12-31
PT3337506T (pt) 2021-09-24
RS62260B1 (sr) 2021-09-30
JP2018523685A (ja) 2018-08-23
JP2023093495A (ja) 2023-07-04
RU2018107929A3 (pl) 2020-01-14
JP2021113194A (ja) 2021-08-05
DK3337506T3 (da) 2021-09-06
JP6862422B2 (ja) 2021-04-21
US20220088197A1 (en) 2022-03-24
AU2022202800A1 (en) 2022-05-19
SMT202100541T1 (it) 2021-11-12
IL297057B2 (en) 2025-11-01
KR20240052084A (ko) 2024-04-22
CN115054697A (zh) 2022-09-16
CA2995738A1 (en) 2017-03-02
NZ739706A (en) 2025-02-28
WO2017032679A1 (en) 2017-03-02
JP2025131697A (ja) 2025-09-09
IL297057B1 (en) 2025-07-01
RU2018107929A (ru) 2019-09-23
US20180228893A1 (en) 2018-08-16
US12194095B2 (en) 2025-01-14
RU2767063C2 (ru) 2022-03-16
MX2022006154A (es) 2022-10-07
IL297057A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL293377A (en) Hsd17b13 variants and uses thereof
IL280863A (en) Autotaxin inhibitors and uses thereof
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3373755T3 (pl) Część do e-palenia i urządzenie do e-palenia oraz sposób ich wytwarzania
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
PL3258951T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
PL4234581T3 (pl) Przeciwciała terapeutyczne i ich zastosowania
KR20180084891A (ko) 구조 조성물 및 방법
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
EP3334706A4 (en) PILLARARES AND USES THEREOF
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania
CL2018000700A1 (es) Sililfenoxiheterociclos trisustituidos y análogos
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
PL3498292T3 (pl) Konstrukty białka uspa2 i ich zastosowania
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3270930T3 (da) Præeklampsi
PL3337506T3 (pl) Kombinacje i ich zastosowania
PL3393485T3 (pl) Kompozycje probiotyczne i ich zastosowanie
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
MA49905A (fr) Polyesteramines et polyesterquats